Phillip M.Shelton Ph.D.

IP Legal Intern

San Diego + 1.858.314.1194

Dr. Phillip Shelton is a registered patent agent and a lawyer-in-training (4L) handling intellectual property matters related to the life sciences and biotech industries. His practice involves drafting and prosecuting patent applications, as well as performing due diligence investigations, patentability and invalidity assessments, freedom-to-operate analyses, and patent strategy counseling.

Exemplary technologies that Phillip has experience handling include cell-based therapeutics (e.g, stem cells and iPS cells), bioengineered microorganisms, CAR-T therapies, neoantigen identification, antibody therapeutics, xenotransplantation, AAV-based therapeutics, clinical diagnostics, pharmacodynamic and diagnostic biomarkers, mitochondrial replacement therapy, and peptide therapeutics, among others.

Prior to joining Jones Day, Phillip worked as a postdoctoral research associate in Jorge Moscat and Maria Diaz-Meco's lab in La Jolla, California, where he investigated the role of microRNAs and extracellular vesicles in promoting colorectal cancer metastases. His doctoral training in molecular toxicology was focused on oncogenic signal transduction pathways responsible for hyper activating the master regulator of antioxidant responses: NRF2. Phillip has coauthored several publications and presented at international research conferences.


  • Hope Pharmaceuticals files two IPR petitions challenging all claims of two Fennec patents relating to sodium thiosulfateJones Day represents Hope Medical Enterprises, Inc. ("Hope Pharmaceuticals") in two petitions for inter partes review ("IPR") at the United States Patent Office's Patent Trial and Appeal Board ("PTAB").
  • Bellicum Pharmaceuticals establishes global patent portfolio related to CAR-T and other cellular immunotherapiesJones Day is representing Bellicum Pharmaceuticals, Inc. in the development and prosecution of global patent portfolios related to cellular immuno-oncology (IO) and immunotherapies, including BPX-601 (PSCA CAR-T) and BPX-603 (Her2 CAR-T) clinical candidates utilizing the Bellicum’s proprietary GoCAR™ technology.
  • Additional Publications

    Publications Prior to Jones Day

    Simultaneous Loss of Both Atypical Protein Kinase C Genes in the Intestinal Epithelium Drives Serrated Intestinal Cancer by Impairing Immunosurveillance, Immunity, 49(6):1132-1147

    Metabolic reprogramming of the tumor microenvironment by p62 and its partners, Biochim Biophys Acta Rev Cancer, 1870(1):88-95

    The Secretion of miR-200s by a PKCζ/ADAR2 Signaling Axis Promotes Liver Metastasis in Colorectal Cancer, Cell Rep., 23(4):1178-1191

    Repression of Intestinal Stem Cell Function and Tumorigenesis through Direct Phosphorylation of β-Catenin and Yap by PKCζ, Cell Rep., 10(5):740-754

    Reactivation of estrogen receptor α by vorinostat sensitizes mesenchymal-like triple-negative breast cancer to aminoflavone, a ligand of the aryl hydrocarbon receptor, PLoS One, 13;8(9):e74525

    The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?, FASEB J, Feb;27(2):414-23